Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 6, 2011, Pages 3309-3320

  Bull, Natalie D ^a   Johnson, Thomas V ^a,b,c   Welsapar, Guncha ^a   DeKorver, Nicholas W ^b   Tomarev, Stanislav I ^b   Martin, Keith R ^a,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NATIONAL EYE INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETAXOLOL; BRAIN DERIVED NEUROTROPHIC FACTOR; BRIMONIDINE; CASPASE INHIBITOR; FORSKOLIN; LOSARTAN; NEURON SPECIFIC NUCLEAR PROTEIN; NEUROPROTECTIVE AGENT; SAFLUTAN; SIMVASTATIN; TAFLUPROST; UNCLASSIFIED DRUG; BENZYLOXYCARBONYLVALYL ALANYL ASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CASPASE; PEPTIDE CHLOROMETHYL KETONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL LOSS; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG SCREENING; EXPLANT; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MESENCHYMAL STEM CELL; NEUROPROTECTION; NONHUMAN; OPTIC NERVE LESION; OXYGEN TENSION; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; ANIMAL; CELL CULTURE; COCULTURE; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; NERVE CRUSH; OPTIC NERVE; OPTIC NERVE DISEASE; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; SPRAGUE DAWLEY RAT; STEM CELL TRANSPLANTATION;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; APOPTOSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASPASES; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FORSKOLIN; MALE; MESENCHYMAL STEM CELLS; NERVE CRUSH; NEUROPROTECTIVE AGENTS; OCULAR HYPERTENSION; OPTIC NERVE; OPTIC NERVE DISEASES; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RETINAL GANGLION CELLS; STEM CELL TRANSPLANTATION;

EID: 79961017064     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6873     Document Type: Article

References (66)

1. Zhang SS, Fu XY, Barnstable CJ. Tissue culture studies of retinal development. Methods. 2002;28:439-447.
2. Bermel C, Tonges L, Planchamp V, et al. Combined inhibition of Cdk5 and ROCK additively increase cell survival, but not the regenerative response in regenerating retinal ganglion cells. Mol Cell Neurosci. 2009;42:427-437.
3. Feigenspan A, Dedek K, Schlich K, Weiler R, Thanos S. Expression and biophysical characterization of voltage-gated sodium channels in axons and growth cones of the regenerating optic nerve. Invest Ophthalmol Vis Sci. 2010;51:1789-1799.
4. Leaver SG, Harvey AR, Plant GW. Adult olfactory ensheathing glia promote the long-distance growth of adult retinal ganglion cell neurites in vitro. Glia. 2006;53:467-476.
5. Manabe S, Kashii S, Honda Y, Yamamoto R, Katsuki H, Akaike A. Quantification of axotomized ganglion cell death by explant culture of the rat retina. Neurosci Lett. 2002;334:33-36.
6. Xin H, Yannazzo JA, Duncan RS, Gregg EV, Singh M, Koulen P. A novel organotypic culture model of the postnatal mouse retina allows the study of glutamate-mediated excitotoxicity. J Neurosci Methods. 2007;159:35-42.
7. Johnson TV, Martin KR. Development and characterization of an adult retinal explant organotypic tissue culture system as an in vitro intraocular stem cell transplantation model. Invest Ophthalmol Vis Sci. 2008;49:3503-3512.
8. Van Bergen NJ, Wood JP, Chidlow G, et al. Recharacterization of the RGC-5 retinal ganglion cell line. Invest Ophthalmol Vis Sci. 2009;50:4267-4272.
9. Johnson TV, Bull ND, Martin KR. Identification of barriers to retinal engraftment of transplanted stem cells. Invest Ophthalmol Vis Sci. 2010;51:960-970.
10. Johnson TV, Bull ND, Hunt DP, Marina N, Tomarev SI, Martin KR. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest Ophthalmol Vis Sci. 2010;51:2051-2059.
11. Levkovitch-Verbin H, Quigley HA, Martin KR, Valenta D, Baumrind LA, Pease ME. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. Invest Ophthalmol Vis Sci. 2002;43:402-410.
12. Yoles E, Schwartz M. Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. Exp Neurol. 1998;153:1-7.
13. Li GY, Osborne NN. Oxidative-induced apoptosis to an immortalized ganglion cell line is caspase independent but involves the activation of poly(ADP-ribose)polymerase and apoptosis-inducing factor. Brain Res. 2008;1188:35-43.
14. Meyer-Franke A, Wilkinson GA, Kruttgen A, et al. Depolarization and cAMP elevation rapidly recruit TrkB to the plasma membrane of CNS neurons. Neuron. 1998;21:681-693.
15. Shen S, Wiemelt AP, McMorris FA, Barres BA. Retinal ganglion cells lose trophic responsiveness after axotomy. Neuron. 1999;23:285-295.
16. Melena J, Stanton D, Osborne NN. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes Arch Clin Exp Ophthalmol. 2001;239:522-530.
17. Grammatopoulos TN, Johnson V, Moore SA, Andres R, Weyhenmeyer JA. Angiotensin type 2 receptor neuroprotection against chemical hypoxia is dependent on the delayed rectifier K+ channel, Na+/Ca2+ exchanger and Na+/K+ ATPase in primary cortical cultures. Neurosci Res. 2004;50:299-306.
18. Matsuda T, Toyohira Y, Ueno S, Tsutsui M, Yanagihara N. Simvastatin inhibits catecholamine secretion and synthesis induced by acetylcholine via blocking Na+ and Ca2+ influx in bovine adrenal medullary cells. J Pharmacol Exp Ther. 2008;327:130-136.
19. Kielczewski JL, Pease ME, Quigley HA. The effect of experimental glaucoma and optic nerve transection on amacrine cells in the rat retina. Invest Ophthalmol Vis Sci. 2005;46:3188-3196.
20. Mojumder DK, Wensel TG, Frishman LJ. Subcellular compartmentalization of two calcium binding proteins, calretinin and calbindin-28 kDa, in ganglion and amacrine cells of the rat retina. Mol Vis. 2008;14:1600-1613.
21. Dijk F, Bergen AA, Kamphuis W. GAP-43 expression is upregulated in retinal ganglion cells after ischemia/reperfusion-induced damage. Exp Eye Res. 2007;84:858-867.
22. Elshatory Y, Deng M, Xie X, Gan L. Expression of the LIM-homeodomain protein Isl1 in the developing and mature mouse retina. J Comp Neurol. 2007;503:182-197.
23. Guo Y, Johnson E, Cepurna W, Jia L, Dyck J, Morrison JC. Does elevated intraocular pressure reduce retinal TRKB-mediated survival signaling in experimental glaucoma? Exp Eye Res. 2009;89: 921-933.
24. Huang W, Fileta J, Guo Y, Grosskreutz CL. Downregulation of Thy1 in retinal ganglion cells in experimental glaucoma. Curr Eye Res. 2006;31:265-271.
25. Soto I, Oglesby E, Buckingham BP, et al. Retinal ganglion cells downregulate gene expression and lose their axons within the optic nerve head in a mouse glaucoma model. J Neurosci. 2008; 28:548-561.
26. Wu KL, Li YQ, Tabassum A, Lu WY, Aubert I, Wong CS. Loss of neuronal protein expression in mouse hippocampus after irradiation. J Neuropathol Exp Neurol. 2010;69:272-280.
27. Lei Y, Garrahan N, Hermann B, et al. Quantification of retinal transneuronal degeneration in human glaucoma: a novel multiphoton-DAPI approach. Invest Ophthalmol Vis Sci. 2008;49:1940-1945.
28. Beirowski B, Babetto E, Coleman MP, Martin KR. The WldS gene delays axonal but not somatic degeneration in a rat glaucoma model. Eur J Neurosci. 2008;28:1166-1179.
29. Buckingham BP, Inman DM, Lambert W, et al. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci. 2008;28:2735-2744.
30. Austin CP, Feldman DE, Ida JA, Jr., Cepko CL. Vertebrate retinal ganglion cells are selected from competent progenitors by the action of Notch. Development. 1995;121:3637-3650.
31. Sanders EJ, Parker E, Aramburo C, Harvey S. Retinal growth hormone is an anti-apoptotic factor in embryonic retinal ganglion cell differentiation. Exp Eye Res. 2005;81:551-560.
32. Genetos DC, Cheung WK, Decaris ML, Leach JK. Oxygen tension modulates neurite outgrowth in PC12 cells through a mechanism involving HIF and VEGF. J Mol Neurosci. 2010;40:360-366.
33. Horie N, So K, Moriya T, et al. Effects of oxygen concentration on the proliferation and differentiation of mouse neural stem cells in vitro. Cell Mol Neurobiol. 2008;28:833-845.
34. Kaplan FS, Brighton CT, Boytim MJ, et al. Enhanced survival of rat neonatal cerebral cortical neurons at subatmospheric oxygen tensions in vitro. Brain Res. 1986;384:199-203.
35. Yu DY, Cringle SJ. Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. Prog Retin Eye Res. 2001;20:175-208.
36. Johnson EC, Guo Y, Cepurna WO, Morrison JC. Neurotrophin roles in retinal ganglion cell survival: lessons from rat glaucoma models. Exp Eye Res. 2009;88:808-815.
37. Johnson TV, Bull ND, Martin KR. Neurotrophic factor delivery as a protective treatment for glaucoma. Exp Eye Res. 2010 [Epub ahead of print, PMID:20685205].
38. Qu J, Wang D, Grosskreutz CL. Mechanisms of retinal ganglion cell injury and defense in glaucoma. Exp Eye Res. 2010;91:48-53.
39. Vrabec JP, Levin LA. The neurobiology of cell death in glaucoma. Eye (Lond). 2007;21 Suppl 1:S11-14.
40. Quigley HA, McKinnon SJ, Zack DJ, et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci. 2000;41:3460-3466.
41. Rudzinski M, Wong TP, Saragovi HU. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. J Neurobiol. 2004;58:341-354.
42. Baptiste DC, Hartwick AT, Jollimore CA, et al. Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina. Invest Ophthalmol Vis Sci. 2002;43:2666-2676.
43. Grieshaber MC, Flammer J. Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?-an exemplary analysis on the basis of two beta-blockers. Prog Retin Eye Res. 2010;29:79-93.
44. Osborne NN, Wood JP, Chidlow G. Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J Ocul Pharmacol Ther. 2005;21:175-181.
45. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci. 2008;49:4515-4522.
46. Dong CJ, Guo Y, Wheeler L, Hare WA. Alpha2 adrenergic receptormediated modulation of cytosolic Ca++ signals at the inner plexiform layer of the rat retina. Invest Ophthalmol Vis Sci. 2007;48: 1410-1415.
47. Villena A, Diaz F, Vidal L, Moreno M, Garcia-Campos J, Perez De Vargas I. Study of the effects of ocular hypotensive drugs on number of neurons in the retinal ganglion layer in a rat experimental glaucoma. Eur J Ophthalmol. 2009;19:963-970.
48. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003;48 Suppl 1:S47-51.
49. Knels L, Worm M, Wendel M, Roehlecke C, Kniep E, Funk RH. Effects of advanced glycation end products-inductor glyoxal and hydrogen peroxide as oxidative stress factors on rat retinal organ cultures and neuroprotection by UK-14,304. J Neurochem. 2008; 106:1876-1887.
50. Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol. 2009;127:402-406.
51. Costagliola C, Verolino M, De Rosa ML, Iaccarino G, Ciancaglini M, Mastropasqua L. Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects. Exp Eye Res. 2000;71:167-171.
52. Sugiyama T, Okuno T, Fukuhara M, et al. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp Eye Res. 2007;85:406-412.
53. Fukuda K, Hirooka K, Mizote M, Nakamura T, Itano T, Shiraga F. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci. 2010;51:3629-3638.
54. Yang H, Hirooka K, Fukuda K, Shiraga F. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Invest Ophthalmol Vis Sci. 2009;50:5800-5804.
55. Kanamori A, Naka M, Fukuda M, Nakamura M, Negi A. Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Graefes Arch Clin Exp Ophthalmol. 2009;247:1353-1360.
56. Kanamori A, Naka M, Fukuda M, Nakamura M, Negi A. Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Exp Eye Res. 2009;88:535-541.
57. Kudo H, Nakazawa T, Shimura M, et al. Neuroprotective effect of latanoprost on rat retinal ganglion cells. Graefes Arch Clin Exp Ophthalmol. 2006;244:1003-1009.
58. Nakanishi Y, Nakamura M, Mukuno H, Kanamori A, Seigel GM, Negi A. Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogenactivated protein kinase. Exp Eye Res. 2006;83:1108-1117.
59. van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: mechanisms of neuroprotection. Prog Neurobiol. 2009;88:64-75.
60. Delanty N, Vaughan CJ, Sheehy N. Statins and neuroprotection. Expert Opin Investig Drugs. 2001;10:1847-1853.
61. Kawaji T, Inomata Y, Takano A, et al. Pitavastatin: protection against neuronal retinal damage induced by ischemia-reperfusion injury in rats. Curr Eye Res. 2007;32:991-997.
62. Kretz A, Schmeer C, Tausch S, Isenmann S. Simvastatin promotes heat shock protein 27 expression and Akt activation in the rat retina and protects axotomized retinal ganglion cells in vivo. Neurobiol Dis. 2006;21:421-430.
63. Schmeer C, Gamez A, Tausch S, Witte OW, Isenmann S. Statins modulate heat shock protein expression and enhance retinal ganglion cell survival after transient retinal ischemia/reperfusion in vivo. Invest Ophthalmol Vis Sci. 2008;49:4971-4981.
64. Johnson-Anuna LN, Eckert GP, Franke C, Igbavboa U, Muller WE, Wood WG. Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007;101: 77-86.
65. Patassini S, Giampa C, Martorana A, Bernardi G, Fusco FR. Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease. Neurosci Lett. 2008;448:166-169.
66. Wu H, Lu D, Jiang H, et al. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma. 2008;25:130-139.